The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease

被引:0
作者
Lee, Ju Kwang [1 ]
Kim, Seonok [2 ]
Chong, Yong Pil [3 ]
Lee, Hyun Joo [4 ]
Shim, Tae Sun [5 ]
Jo, Kyung-Wook [5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Infect Dis, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
all-cause mortality; cavitary type; Mycobacterium avium complex; treatment outcome; TREATMENT OUTCOMES; LUNG-DISEASE; TUBERCULOSIS;
D O I
10.1016/j.chest.2024.03.027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: The association between treatment outcome and the mortality of patients with Mycobacterium avium complex pulmonary disease (MAC-PD) with cavitary lesions is unclear. This article assessed the impact of culture conversion on mortality in patients with cavitary RESEARCH QUESTION: Is the achievement of sputum culture conversion in patients with MAC-PD with cavitary lesions associated with the prognosis? STUDY DESIGN AND METHODS: From 2002 to 2020, a total of 351 patients with cavitary MAC-PD (105 with the fibrocavitary type and 246 with the cavitary nodular bronchiectatic type), who had been treated with a >= 6-month macrolide-containing regimen at a tertiary referral center in South Korea, were retrospectively enrolled in this study. All-cause mortality during the follow-up period was analyzed based on culture conversion at the time of treatment completion. RESULTS: The cohort had a median treatment duration of 14.7 months (interquartile range [IQR], 13.4-16.8 months). Of the 351 patients, 69.8% (245 of 351) achieved culture conversion, and 30.2% (106 of 351) did not. The median follow-up was 4.4 years (IQR, 2.3-8.3 years) in patients with culture conversion and 3.1 years (IQR, 2.1-4.8 years) in those without. For the patients with and without culture conversion, all-cause mortality was 5.3% vs 35.8% (P < .001), and the 5-year cumulative mortality was 20.0% vs 38.4%, respectively. Cox analysis found that a lack of culture conversion was significantly associated with higher mortality (adjusted hazard ratio, 5.73; 95% CI, 2.86-11.50). Moreover, the 2-year landmark analysis revealed a distinct impact of treatment outcome on mortality. INTERPRETATION: The mortality rate of patients with cavitary MAC-PD who did not achieve culture conversion was significantly higher than that of those with culture conversion.
引用
收藏
页码:442 / 451
页数:10
相关论文
共 31 条
  • [11] Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Baek, Sun-Young
    Sohn, Insuk
    Jhun, Byung Woo
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 12
  • [12] BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease
    Kim, Hyung-Jun
    Kwak, Nakwon
    Hong, Hyunsook
    Kang, Noeul
    Im, Yunjoo
    Jhun, Byung Woo
    Yim, Jae-Joon
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (02) : 230 - 236
  • [13] Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype
    Koh, Won-Jung
    Moon, Seong Mi
    Kim, Su-Young
    Woo, Min-Ah
    Kim, Seonwoo
    Jhun, Byung Woo
    Park, Hye Yun
    Jeon, Kyeongman
    Huh, Hee Jae
    Ki, Chang-Seok
    Lee, Nam Yong
    Chung, Myung Jin
    Lee, Kyung Soo
    Shin, Sung Jae
    Daley, Charles L.
    Kim, Hojoong
    Kwon, O. Jung
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (03)
  • [14] Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis
    Kwak, Nakwon
    Park, Jimyung
    Kim, Eunyoung
    Lee, Chang-Hoon
    Han, Sung Koo
    Yim, Jae-Joon
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 65 (07) : 1077 - 1084
  • [15] Discontinuation rates attributed to adverse events and treatment outcomes between clarithromycin and azithromycin in Mycobacterium avium complex lung disease: A propensity score analysis
    Kwon, Yong Shik
    Han, Minkyu
    Kwon, Byoung Soo
    Kim, Ock-Hwa
    Lee, Ho-Young
    Shim, Tae Sun
    Chong, Yong Pil
    Jo, Kyung-Wook
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 22 : 106 - 112
  • [16] Treatment of Mycobacterium avium Complex Pulmonary Disease
    Kwon, Yong-Soo
    Koh, Won-Jung
    Daley, Charles L.
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2019, 82 (01) : 15 - 26
  • [17] Mortality and Prognostic Factors of Nontuberculous Mycobacterial Infection in Korea: A Population-based Comparative Study
    Lee, Hyewon
    Myung, Woojae
    Lee, Eun-Mi
    Kim, Hyekyeong
    Jhun, Byung Woo
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (10) : E610 - E619
  • [18] Lee JH, 2022, ANTIMICROB AGENTS CH, V66, DOI [10.1128/aac.01522-21, 10.1128/AAC.01522-21]
  • [19] Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection
    Martiniano, Stacey L.
    Wagner, Brandie D.
    Levin, Adrah
    Nick, Jerry A.
    Sagel, Scott D.
    Daley, Charles L.
    [J]. CHEST, 2017, 152 (04) : 800 - 809
  • [20] Meghji J, 2020, THORAX, V75, P269, DOI [10.1136/thoraxjnl-2019-213808, 10.1136/thoraxjnl-2020-214580]